Great West Life Assurance Co. Can Has $4.70 Million Stake in Mednax, Inc (NYSE:MD)
Great West Life Assurance Co. Can boosted its stake in Mednax, Inc (NYSE:MD) by 0.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 77,858 shares of the company’s stock after buying an additional 510 shares during the period. Great West Life Assurance Co. Can’s holdings in Mednax were worth $4,698,000 as of its most recent filing with the SEC.
A number of other large investors have also recently added to or reduced their stakes in the company. Longview Partners Guernsey LTD raised its stake in Mednax by 10.3% in the second quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after buying an additional 467,845 shares in the last quarter. LGT Capital Partners LTD. raised its stake in Mednax by 38.3% in the second quarter. LGT Capital Partners LTD. now owns 215,390 shares of the company’s stock valued at $13,003,000 after buying an additional 59,650 shares in the last quarter. First Citizens Bank & Trust Co. raised its stake in Mednax by 56.0% in the second quarter. First Citizens Bank & Trust Co. now owns 8,019 shares of the company’s stock valued at $484,000 after buying an additional 2,879 shares in the last quarter. BB&T Corp raised its stake in Mednax by 5.4% in the second quarter. BB&T Corp now owns 151,766 shares of the company’s stock valued at $9,163,000 after buying an additional 7,793 shares in the last quarter. Finally, State Treasurer State of Michigan raised its stake in Mednax by 0.5% in the second quarter. State Treasurer State of Michigan now owns 38,300 shares of the company’s stock valued at $2,312,000 after buying an additional 200 shares in the last quarter.
Shares of Mednax, Inc (NYSE MD) opened at 42.93 on Tuesday. Mednax, Inc has a one year low of $41.52 and a one year high of $72.13. The stock has a market capitalization of $3.96 billion, a price-to-earnings ratio of 13.67 and a beta of 0.40. The firm’s 50-day moving average is $53.67 and its 200-day moving average is $61.14.
Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business’s revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.03 earnings per share. Equities research analysts forecast that Mednax, Inc will post $3.31 EPS for the current year.
Several research firms recently issued reports on MD. BidaskClub lowered shares of Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Mizuho reissued a “neutral” rating and issued a $48.00 target price (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Jefferies Group LLC set a $46.00 target price on shares of Mednax and gave the stock a “hold” rating in a report on Sunday, July 30th. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $55.00 to $68.00 in a report on Thursday, June 22nd. Finally, ValuEngine lowered shares of Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $64.00.
In related news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the sale, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now owns 296,379 shares of the company’s stock, valued at $16,300,845. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.